title: A randomized trial of methotrexate versus azathioprine for severe atopic eczema.
abstract: BACKGROUND
  Patients with severe atopic eczema frequently require systemic treatment to control their disease. Methotrexate and azathioprine are proposed as off-label treatment options, but direct comparisons are lacking.
  
  
  OBJECTIVE
  We sought to compare the efficacy and safety of methotrexate versus azathioprine in adults with severe atopic eczema.
  
  
  METHODS
  Patients with severe atopic eczema were randomly assigned in a 1:1 ratio to receive either methotrexate (dosage, 10-22.5 mg/wk) or azathioprine (dosage, 1.5-2.5 mg/kg/d) for 12 weeks, followed by a 12-week follow-up period. Primary outcome was the mean change in the severity scoring of atopic dermatitis index after 12 weeks. Efficacy assessors blinded for allocation of treatment were used to perform clinical outcome assessment. Analyses were done on an intention-to-treat basis.
  
  
  RESULTS
  Of the 45 patients screened, 42 were included. At week 12, patients in the methotrexate group had a mean relative reduction in the severity scoring of atopic dermatitis index of 42% (SD, 18%) compared with 39% (SD, 25%) in the azathioprine group (P = .52). Proportions of patients achieving at least mild disease and reductions on impact of quality of life, symptoms, and levels of thymus and activation-regulated chemokine were similar in both groups at weeks 12 and 24. No statistically significant differences were found in the number and severity of adverse events. Abnormalities in blood count were more common in the azathioprine group. No serious adverse events occurred.
  
  
  CONCLUSIONS
  Both treatments achieved clinically relevant improvement and were safe in the short term. Methotrexate and azathioprine are appropriate options for the treatment of severe atopic eczema.
authors.affiliation: Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. M.E.Schram@amc.uva.nl
authors.forename: Mandy Elvira
authors.initials: ME
authors.lastname: Schram
authors.forename: Evelien
authors.initials: E
authors.lastname: Roekevisch
authors.forename: Mariska Maria Geertruida
authors.initials: MM
authors.lastname: Leeflang
authors.forename: Jan Dositheus
authors.initials: JD
authors.lastname: Bos
authors.forename: Jochen
authors.initials: J
authors.lastname: Schmitt
authors.forename: Phyllis Ira
authors.initials: PI
authors.lastname: Spuls
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D001379:Azathioprine; D008727:Methotrexate